AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide
By Lori Solomon HealthDay Reporter
FRIDAY, Nov. 22, 2024 -- More than half of all U.S. adults are eligible for semaglutide therapy, according to a research letter published online Nov. 18 in JAMA Cardiology to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.
Ivy Shi, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues used data from 25,531 participants in the National Health and Nutrition Examination Survey (2015 to March 2020) to quantify the number of U.S. adults eligible for semaglutide. Eligibility criteria included: (1) diabetes; (2) weight management (body mass index [BMI] ≥30 kg/m2 or BMI ≥27 kg/m2 with a weight-related comorbidity [hypertension, hyperlipidemia, or history of myocardial infarction or stroke]); and (3) secondary prevention of cardiovascular disease (CVD; aged 45 years or older, BMI ≥27 kg/m2, and a history of myocardial infarction or stroke).
The researchers found that semaglutide was indicated for an estimated 35.0 million adults for diabetes management, 129.2 million adults for weight management, and 8.9 million adults for secondary prevention of CVD. Of the 39.3 million U.S. adults eligible for semaglutide for diabetes or secondary prevention of CVD, 13.0 million were insured by Medicare and 4.7 million were insured by Medicaid.
"Efforts to increase equitable uptake should be coupled with strategies to ensure that the cost of semaglutide is commensurate with the value of the health benefits it produces," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Doctors Favor CPAP, Patients Favor Tirzepatide for Comorbid Obesity, Sleep Apnea
MONDAY, June 9, 2025 -- Both continuous positive airway pressure (CPAP) and tirzepatide are acceptable treatments for comorbid obesity and obstructive sleep apnea (COBOSA), with...
Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM
MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...
Less 'Experienced Weight Stigma' After Bariatric Surgery Aids Mental Health
FRIDAY, June 6, 2025 -- Experienced weight stigma (EWS) improves from pre- to post-metabolic bariatric surgery (MBS), according to a study published online June 5 in Health...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.